Fair value measurements (Tables)

6 Months Ended

Jul. 01, 2023

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:

	July 1, 2023				December 31, 2022
	Total		Level 3		Total		Level 3
Liabilities:
Deferred Amount - Current(a)	$	—	$	—	$	117,615	$	117,615
Deferred Amount - Long Term(a)	—		—		79,269		79,269
CartiHeal contingent consideration- Sales Milestone(a)	—		—		67,251		67,251
Bioness contingent consideration	17,958		17,958		17,431		17,431
Total liabilities:	$	17,958	$	17,958	$	281,566	$	281,566

(a)The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to Note 3. Acquisitions and divestitures and Note 14. Discontinued operations for further details regarding the deconsolidation of CartiHeal.

Schedule of Fair Value Measurement Inputs and Valuation Techniques

A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:

	Valuation Technique	Unobservable inputs	Range
Bioness contingent consideration	Discounted cash flow	Payment discount rate	6.4% - 6.8%
		Payment period	2024 - 2025